We look forward to a great number of compelling studies being presented across our plenary sessions. Daily press releases will be published on these studies.
Here are just some of the highly anticipated studies due to be covered at this year’s conference:
- TESLA (Thrombectomy for Emergent Salvage of Large Anterior Circulation Ischemic Stroke) and the MAGNA (MechAnical thrombectomy for larGe braiN infArctions) collaboration will focus on looking at reperfusion therapy in patients with large core anterior circulation infarct.
- VECTOR (Adaptative Endovascular Strategy to the CloT MRI in Largeintracranial Vessel Occlusion) is a multi-centre trial particular of interest in patients with a susceptibility vessel sign on MRI. The trial will compare the current first-line strategy in endovascular treatment with stent retriever added to contact aspiration versus contact aspiration alone.
- INDIVIDUATE (Effect of Individualized Versus Standard Blood Pressure Management During Endovascular Stroke Treatment Under Procedural Sedation on Clinical Outcome) aims to compare an individualised blood pressure management approach in which intra-procedural blood pressure targets were set to pre-interventional values versus a standardised blood pressure approach.
- PERFEQTOS (Performance Feedback to Improve Time to Thrombectomy for Ischemic Stroke: a stepped wedge cluster randomized trial) evaluated if a performance feedback intervention reduced treatment delays in patients underlying endovascular treatment.
- OPTIMAL-BP focuses on another important aspect after successful thrombectomy. They investigated whether intensive blood pressure management (target systolic blood pressure <140mmHg) during the first 24 hours after successful recanalization vs. conventional management (targeting systolic blood pressure 140-180mmHg) improved functional outcome at 3 months.
- TIMELESS is a phase-III, double-blind, randomised, placebo-controlled trial of tenecteplase in patients with acute ischaemic stroke and evidence of salvageable tissue on imaging who presented 4.5-24 hours after last seen well with an anterior circulation large vessel occlusion. The study aims to compare intravenous tenecteplase (0.25mg/kg) versus placebo in improving functional outcome at 90 days.
Other acute management:
- PRECIOUS (Prevention of Complications to Improve Outcome In Elderly Patients with Acute Stroke) focused on patients aged 66 years or older with ischaemic stroke or intracerebral haemorrhage and tested if preventive antiemetic, antibiotic or antipyretic therapy improved functional outcome if they were started within 24 hours after symptom onset and continued for 4 days or until discharge.
- RESIST (Remote Ischemic Conditioning In Patients with Acute Stroke) investigated if remote ischaemic conditioning started in the ambulance and continued in-hospital improved functional outcome in patients with acute ischemic or haemorrhagic stroke presenting within 4 hours.